TrialsgrambetaRCTs are beautiful

BENEFIT

2016

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial

In 666 kidney-transplant recipients, belatacept improved 7-year patient and graft survival compared with ciclosporin.

Result

Efficacy: Death or graft loss at 7 yearsHR 0.57 (95% CI 0.35-0.95) · P = 0.02

Below 1 favours belatacept, above 1 favours ciclosporin.

Also reported: Mean eGFR ~70 vs ~45 mL/min.

Original publication
Subtopic
Belatacept
Design
Phase 3 RCT, 7-year follow-up
Relevance
Important: one of several pillars.
Source
Vincenti F, et al. N Engl J Med. 2016;374(4):333-343.doi 10.1056/NEJMoa1506027

Discussion & critique

A CNI-free alternative with better kidney function; post-transplant lymphoproliferative risk restricts it to EBV-seropositive recipients.